Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8597557 | 0.91 | ADORA3 (0.32) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL8542668 | 0.84 | ALDH1A1 (0.37) | ALDH1A1ADORA3MAPT | |
| SCHEMBL4244108 | 0.81 | ALDH1A1 (0.34) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL905936 | 0.74 | ALDH1A1 (0.34) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL663382 | 0.74 | SLC6A9 (0.36) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL30803820 | 0.73 | ADORA2A (0.37) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL7717266 | 0.73 | ADORA2A (0.37) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL8936038 | 0.73 | ADORA2A (0.37) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL8935948 | 0.72 | ADORA2A (0.36) | ALDH1A1LMNAHTTL3MBTL1ADORA3 | |
| SCHEMBL8547909 | 0.69 | KDR (0.37) | ALDH1A1LMNAHTTL3MBTL1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040022735-A1 | Enzyme activated contrast agents | GENERAL ELECTRIC COMPANY | 2004-02-05 | — | — | US | claimed |
| US-20020076378-A1 | Polymers | NYCOMED IMAGING AS | 2002-06-20 | — | — | US | claimed |
| US-20160152687-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9296809-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9221896-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150329619-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150203568-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8993517-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8969538-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303077-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-0624097-B1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1998-03-18 | — | — | EP | disclosed |
| US-5707603-A | Pyridine complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions | NYCOMED IMAGING AS (NO) | 1998-01-13 | — | — | US | disclosed |
| US-5677445-A | DIAGNOSIS, THERAPY | NYCOMED IMAGING AS (NO) | 1997-10-14 | — | — | US | disclosed |
| US-5523402-A | COMPLEXING AGENTS FOR TARGETING RADIOACTIVE IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0639083-A1 | COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1995-02-22 | — | — | EP | disclosed |
| US-5367080-A | PYRIDINE DERIVATIVES | STERLING WINTHROP INC. (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0624097-A1 | TARGETING RADIOACTIVE IMMUNOREAGENTS | NYCOMED IMAGING AS (NO) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993021957-A1 | COMPLEXING AGENTS AND TARGETING IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1992008494-A2 | TARGETING RADIOACTIVE IMMUNOREAGENTS | STERLING WINTHROP INC. (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329619-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | ALDH1A1 2350/4885LMNA 2158/4885HTT 183/4885 |
| US-20150203568-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | ALDH1A1 2350/4885LMNA 2158/4885HTT 183/4885 |
| US-20160152687-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | ALDH1A1 2350/4885LMNA 2158/4885HTT 183/4885 |
| US-20140303077-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | ALDH1A1 2350/4885LMNA 2158/4885HTT 183/4885 |
| US-20020076378-A1 | Polymers | PARG, PAICS, PIGO | ALDH1A1 2505/4885LMNA 2995/4885HTT 1563/4885 |
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, IAPP | ALDH1A1 2321/4885LMNA 2320/4885HTT 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.